Застосування комплексу на основі магнію та калію (Панцикор) на перебіг артеріальної гіпертензії І-ІІ стадії 1-2-го ступеня з гіпокаліємією

Abstract

High blood pressure (BP) is noted in 34.8% of the population of Ukraine. Antihypertensive therapy is used by 34.4% of patients, by 14% - a treatment is effective. Resistance to antihypertensive therapy can be caused by a number of reasons, one of which is electrolyte imbalance. Purpose - to analyze the possibilities of using the complex Panzikor in patients with arterial hypertension of the I-II degree and hypokalemia to achieve the target level of blood pressure. Materials and methods. It is examined 34 (57%) patients with hypertension of the 1st degree and 26 (43%) patients with hypertension of the 2nd degree. All subjects were divided into groups: A (n=17) and C (n=13) - patients with AH of 1-2 degree who were prescribed standard antihypertensive therapy and Panzikor (1 sachet once a day for 12 weeks); B (n=17) and D (n=13) - patients with hypertension of 1-2 degree who were prescribed standard antihypertensive therapy. All patients underwent a general clinical examination, determination of potassium and sodium levels in the blood, carbohydrate and lipid parameters. Diaries of medication use and blood pressure measurement were kept. Results. After treatment, a significant decrease in blood pressure was recorded: in the Group A - systolic blood pressure from 156.1±12.2 mm Hg to 131.3±9.1 mm Hg and diastolic blood pressure from 99.7±6.3 mm Hg to 82.1±6.2 mm Hg; in the Group C - systolic blood pressure from 166.3±14.5 mm Hg to 139.4±11.2 mm Hg, diastolic blood pressure from 104.1±7.9 mm Hg to 86.1±6.3 mm Hg. In the Groups B and D, no significant decrease in blood pressure was found. Patients of the Groups A and C showed positive dynamics of blood glucose reduction (in the Group A - from 5.4±0.8 mmol/l to 4.2±0.6 mmol/l; in the Group C - from 4.7±1.3 mmol/l to 4.2±1.1 mmol/l), glycosylated hemoglobin (in the Group A - from 5.2±1.1% to 4.6±1.2%; in the Group C - from 5.1±0.8% to 4.8±0.7%), total cholesterol (in the Group A - from 5.6±1.3 mmol/l to 4.2±1.1 mmol/l; in the Group C - from 5.8±2.7 mmol/l to 4.3±1.1 mmol/l), low density lipoproteins (in the Group A - from 2.9±1.1 mmol/l to 1.5±0.4 mmol/l; in the Group C - from 3.2±1.2 7 mmol/l to 1.8±0.7 mmol/l). Conclusions. Panzikor should be prescribed to patients with hypertension and hypokalemia to effectively achieve target blood pressure levels and stabilize lipid and carbohydrate metabolism indicators. The study was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institution mentioned in the work. No conflict of interests was declared by the authors.